Interleukin-6 – Medxy AI

Interleukin 6 as a Treatment Target for Depression: A Proof-of-Concept Randomized Clinical Trial

By MedXY 06/03/2026

A small randomized trial found that blocking IL-6 with tocilizumab showed promising, clinically meaningful trends for inflammation-related, hard-to-treat depression, especially for somatic symptoms, fatigue, anxiety, and quality of life, though results were not statistically significant.

Cardiology Internal Medicine news

Higher Interleukin-6 Levels Predict Broad Cardiovascular Risk and Mortality Across Diverse Cohorts

By MedXY 05/31/2026

A pooled analysis of 59,396 participants found that higher serum IL-6 concentrations independently predicted nine cardiovascular and mortality outcomes, with consistent associations across key clinical subgroups.

Diabetes & Endocrinology news Ophthalmology

Tocilizumab Shows Promising Benefits in Glucocorticoid-Resistant Thyroid Eye Disease

By MedXY 05/13/2026

In two prospective cohorts of active, glucocorticoid-resistant thyroid eye disease, tocilizumab improved eye inflammation, proptosis, diplopia, and quality of life with acceptable safety, supporting IL-6 blockade as a promising second-line treatment.

Cardiology Nephrology news

Interleukin-6 Inhibition: A New Frontier in Reducing Residual Cardiovascular and Renal Risk

By MedXY 01/16/2026

Recent clinical evidence identifies Interleukin-6 (IL-6) as a critical driver of cardiovascular events. The ZEUS trial and recent LoDoCo2 analyses suggest that targeting IL-6 with ziltivekimab may significantly reduce risk for patients with chronic kidney disease and elevated lipoprotein(a).